Evolution of knowledge on the etiological diagnosis of chagasic infection

Luquetti, Alejandro O.

doi:10.1590/s0074-02761999000700050

Cited by 7 publications

(6 citation statements)

References 17 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In an examination of sera from children in the acute phase and in early chronic phase following treatment, other investigators reported similar declines in antibody recognition after several years of follow-up (1,33,44). Considering the high sensitivity and specificity of the CoML test in detecting lytic antibodies and the absence of significant difference between the positive percentage reduction tendencies of this test and the rCRP ELISA in the posttherapeutic patient evaluation, we conclude that the rCRP ELISA is an efficient and specific indicator of parasite clearance and suggest its use as a cure criterion.…”

Section: Discussionmentioning

confidence: 74%

Use of theTrypanosoma cruziRecombinant Complement Regulatory Protein To Evaluate Therapeutic Efficacy following Treatment of Chronic Chagasic Patients

Meira

Galvão²,

Gontijo

et al. 2004

J Clin Microbiol

View full text Add to dashboard Cite

One of the greatest concerns in Chagas' disease is the absence of reliable methods for the evaluation of chemotherapy efficacy in treated patients. The tests available to evaluate cure after the specific treatment are the complement-mediated lysis (CoML) and flow cytometry tests, but they are not feasible for routine clinical use. In this study, we evaluated an enzyme-linked immunosorbent assay (ELISA) based on the recombinant Trypanosoma cruzi complement regulatory protein (rCRP) as a method to determine parasite clearance in comparison to the CoML and other methods such as conventional serology, hemoculture, and PCR in serum samples of 31 patients collected before and after the treatment, monitored for an average of 27.7 months after chemotherapy. The results showed that the percentage of patient samples that were positive by rCRP ELISA was reduced from 100 to 70.3, 62.5, 71.4, and 33.4% in the first, second, third, and fourth years after treatment, respectively, while the samples positive by CoML were reduced to 85.2, 81.2, 71.4, and 33.4% during the same period, demonstrating the same significant tendency in the reduction of positive samples. On the other hand, the conventional serology (CS) tests did not present this reduction. The percentage of samples positive by PCR was initially 77.4% and decreased to 55.5, 68.7, 47.7, and 50.0% at the fourth year after treatment, confirming the drastic clearance of circulating parasites after treatment. Our results strongly suggest that the rCRP ELISA was capable of detecting the early therapeutic efficacy in treated patients and confirmed its superiority over the CS tests and parasitologic methods.

show abstract

Section: Discussionmentioning

confidence: 74%

Use of theTrypanosoma cruziRecombinant Complement Regulatory Protein To Evaluate Therapeutic Efficacy following Treatment of Chronic Chagasic Patients

Meira

Galvão²,

Gontijo

et al. 2004

J Clin Microbiol

View full text Add to dashboard Cite

show abstract

“…On the other hand, serology became negative after successful parasitological treatment of both acute and chronic infection, indicating cure from the infection (Luquetti 1999). A negative parasitological test alone does not represent treatment success; however, its positivity after chemotherapy represents therapeutic failure.…”

Section: Resultsmentioning

confidence: 99%

Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up

Fernandes

Tiecher

Balbinot

et al. 2009

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

“…As described by Luquetti (1999), improvements in diagnosis can be seen to have occurred during a number of key periods: during the first period, from discovery until 1960, diagnosis was performed using XD for parasitological research and using complement fixation reaction (CFR) for serological diagnosis of the chronic phase. During a second period, from [1960][1961][1962][1963][1964][1965][1966][1967][1968][1969][1970][1971][1972][1973][1974][1975], major progress was made.…”

mentioning

confidence: 99%

Diagnosis of Chagas disease: what has been achieved? What remains to be done with regard to diagnosis and follow up studies?

Gomes

Lorena

Luquetti

2009

Mem. Inst. Oswaldo Cruz

Self Cite

118

107

View full text Add to dashboard Cite

Evolution of knowledge on the etiological diagnosis of chagasic infection

Cited by 7 publications

References 17 publications

Use of theTrypanosoma cruziRecombinant Complement Regulatory Protein To Evaluate Therapeutic Efficacy following Treatment of Chronic Chagasic Patients

Use of theTrypanosoma cruziRecombinant Complement Regulatory Protein To Evaluate Therapeutic Efficacy following Treatment of Chronic Chagasic Patients

Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up

Diagnosis of Chagas disease: what has been achieved? What remains to be done with regard to diagnosis and follow up studies?

Contact Info

Product

Resources

About